1201196-54-4

Basic information

• Product Name: 4-bromo-1-chloro-2-cyclopropoxybenzene
• Synonyms: 4-bromo-1-chloro-2-cyclopropoxybenzene
• CAS NO: 1201196-54-4
• Molecular Weight: 247.519
• Mol File: 1201196-54-4.mol

Chemical Properties

• CAS DataBase Reference: 4-bromo-1-chloro-2-cyclopropoxybenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-1-chloro-2-cyclopropoxybenzene(1201196-54-4)
• EPA Substance Registry System: 4-bromo-1-chloro-2-cyclopropoxybenzene(1201196-54-4)

Safety Data

• Hazardous Substances Data: 1201196-54-4(Hazardous Substances Data)

Upstream product

• 4333-56-6 cyclopropyl bromide 
• 183802-98-4 5-bromo-2-chlorophenol 

Relevant articles and documents

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and compounds I for use to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).

HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS

The present invention is concerned with novel sulfonamides of formula wherein R1, R2, R3, R4, R5, Ar, Ar1, Ar2, n, o and p are as described in the description and claims. The compounds are orexin receptor antagonists that may be useful in the treatment of disorders, in which orexin pathways are involved.